title: MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS.
abstract: MicroRNAs (miRNAs) play several important roles in carcinogenesis, and the dysregulation of miRNAs is associated with cancer progression. Little is known about the role of miR-613 in ovarian cancer. In the present study, we demonstrate that miR-613 expression is downregulated in human ovarian cancer cell lines and tissues. Additionally, miR-613 overexpression suppressed ovarian cancer cell proliferation, colony formation, and invasion. Furthermore, KRAS was identified as a target of miR-613. Reintroducing KRAS rescued the inhibitory effects exerted by miR-613 on ovarian cancer cell proliferation and invasion. Taken together, our findings suggest that miR-613 functions as a candidate tumor suppressor miRNA in ovarian cancer by directly targeting KRAS. To the best of our knowledge, this is the first study to show that miR-613 affects the proliferation and invasion of ovarian cancer.
authors.affiliation: Department of Gynecology Cancer, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China. fxhappy@126.com.
authors.forename: Xin
authors.initials: X
authors.lastname: Fu
authors.affiliation: Department of Gynecology Cancer, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
authors.forename: Yanfen
authors.initials: Y
authors.lastname: Cui
authors.affiliation: Department of Gynecology Cancer, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
authors.forename: Shaobin
authors.initials: S
authors.lastname: Yang
authors.affiliation: Department of Gynecology Cancer, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China. zzcsd1@sina.com.
authors.forename: Zicheng
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D020413:3' Untranslated Regions; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D049109:Cell Proliferation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000473:pathology*; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D034622:RNA Interference
chemical_list: D020413:3' Untranslated Regions; C117307:KRAS protein, human; C561374:MIRN613 microRNA, human; D035683:MicroRNAs; D016283:Proto-Oncogene Proteins p21(ras)
keywords: KRAS; MicroRNAs; Ovarian cancer; miR-613